News

July 18, 2023

Cellphire Therapeutics Issued New Core Technology Patent covering FPH technology as an Antiplatelet Reversal Agent

Cellphire Therapeutics, Inc. was issued a patent entitled "Thrombosomes as an Antiplatelet Reversal Agent" (Patent US 11,701,388 B2 ('388 Patent)) covering the application of our Freeze-Dried Platelet-Derived Hemostat Technology (FPH) to restore hemostasis on patients bleeding as a result of all classes of antiplatelet antagonists.

April 18, 2023

First patient treated in Phase 2 clinical trial of Thrombosomes® in Acute Thoracic Aortic Dissections (TTAD)

Cellphire Therapeutics announced today the enrollment and treatment of the first patient in an investigator-initiated clinical trial in Denmark.

March 7, 2023

Cellphire Therapeutics Conducted CPP Investigator Meeting

Cellphire Therapeutics conducted first in-person investigator meeting in San Diego focused on our Cryopreserved Platelet Product.

February 13, 2023

Cellphire Therapeutics Published in Journal of Cardiothoracic and Vascular Anesthesia

Cellphire Therapeutics is proud to announce the publication of “In Vitro Treatment of Extracorporeal Membrane Oxygenation (ECMO) Coagulopathy with Recombinant von Willebrand Factor or Lyophilized Platelets” in the Journal of Cardiothoracic and Vascular Anesthesia.

December 20, 2022

Cellphire Therapeutics Issued New Core Technology Patent (Materials and Methods for Producing Blood Products)

Cellphire Therapeutics is excited to announce the United States Patent Office (USPTO) issued a patent, entitled Materials and Methods for Manufacturing Blood Products (Patent 11,529,587 B2 ('587 Patent) covering a new innovation in the method used to produce Thrombosomes®.

May 2, 2022

Cellphire Therapeutics Names Anya Derbij, MD as Vice President of Clinical Operations

Dr. Derbij has worked for over 20 years in industry and joins the team as Vice President of Clinical Operations after successfully managing a pivotal trial in ophthalmic gene therapy during the worst of the COVID-19 pandemic.

March 31, 2022

Cellphire Therapeutics Treats First Patient in Phase 2/3 Cryopreserved Platelets Clinical Trial

Cellphire Therapeutics announced today that the 1st patient has been treated in its Phase 2/3 clinical trial, Randomized Controlled Trial Comparing Dimethyl Sulfoxide (DMSO) Cryopreserved Platelets to Liquid Stored Platelets in Patients Undergoing Cardiopulmonary Bypass Surgery (CRYPTICS).

February 8, 2022

Cellphire Therapeutics Appoints Pamela B. Conley to its Board of Directors

Announced today the appointment of Pamela B. Conley, Ph.D. to the company’s Board of Directors.